Management of pediatric plaque psoriasis using biologics - 11/12/19
, James N. Bergman, MD d, Loretta Fiorillo, MD e, Marissa Joseph, MD b, c, Irene Lara-Corrales, MSc, MD c, Danielle Marcoux, MD f, Catherine McCuaig, MD f, Elena Pope, MSc, MD c, Vimal H. Prajapati, MD g, Sue Z.J. Li, PhD h, Ian Landells, MD iAbstract |
Background |
Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect adults and children. In adults, biologics have revolutionized the treatment of moderate to severe plaque psoriasis where clear or almost clear is a tangible goal. Research on biologics has recently been extended to children. The introduction of these new therapeutic options has outpaced the limited guidelines in this population.
Objective |
To provide a review of current data on biologics, with a proposal for a clinically relevant treatment algorithm on the management of moderate to severe plaque psoriasis in the pediatric population.
Methods |
A Canadian panel with expertise in psoriasis, pediatric dermatology, and experience with consensus recommendation processes was selected to review the current landscape of pediatric psoriasis and clinical data on biologics plus identify special considerations for baseline workup and monitoring. Recommendations were reviewed and edited by each expert in an iterative process.
Conclusion |
A treatment algorithm for moderate to severe plaque psoriasis in pediatric patients is presented, incorporating approved biologics. Guidance on baseline screening and ongoing monitoring is also provided. Ultimately, treatment choice depends on the patient and his or her caregiver, with consideration of comorbidities, impact on quality of life, and relevant safety aspects.
Le texte complet de cet article est disponible en PDF.Key words : adolescent, biologics, children, monitoring, pediatric, psoriasis, systemic therapy
Abbreviations used : AEs, IL, MTX, PASI, RCTs, TB, Th17, TNF-α
Plan
| Funding sources: The authors first discussed this topic at an advisory board convened by Janssen Inc Canada on September 16, 2016. Janssen Inc Canada did not provide financial writing support to any of the authors. |
|
| Conflicts of interest: Dr Lansang: Consultant, speaker, or advisory boards for Amgen, AbbVie, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis, and Valeant. Dr Bergman: Advisory board and/or speaker for Aralez, Cipher, Galderma, GSK, Janssen, LEO Pharma, Novartis, Pfizer, and Valeant. Dr Fiorillo: Investigator for Celgene and Pfizer and advisory boards for Janssen, Novartis, Amgen, and AbbVie. Dr Joseph: Consultant, speaker, or advisory board for Janssen, Novartis, Amgen, and AbbVie. Dr Lara-Corrales: Advisory boards, consultant, speaker, and/or investigator for AbbVie, Amgen, Celgene, Janssen, LEO Pharma, Eli Lilly, and AbbVie; and consultant, speaker, or advisory boards for Janssen, Amgen, Pfizer, Novartis, AbbVie. Dr Marcoux: Investigator for Galderma, LEO Pharma, Eli Lily, AbbVie, Celgene, and Janssen; advisory boards for Galderma, LEO Pharma, Eli Lilly, AbbVie, Celgene, Janssen, and Amgen; and speaker for AbbVie, LEO Pharma, and Celgene. Dr McCuaig: Advisory boards for Janssen, Novartis, Amgen, AbbVie, and Celgene. Dr Pope: Investigator for Amgen and Centocor and advisory board for Janssen. Dr Prajapati: Investigator for AbbVie, Asana, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, and Regeneron; and consultant, advisor, and/or speaker for AbbVie, Actelion, Amgen, Aralez, Aspen, Celgene, Cipher, Eli Lilly, Galderma, GlaxoSmithKline, Homeocan, Janssen, LEO Pharma, L'Oreal, Novartis, Pfizer, Sanofi Genzyme, Tribute, and Valeant. Dr Li is an employee of Janssen Inc Canada. Dr Landells: Investigator for Janssen and Eli Lily, and consultant, advisor, and/or speaker for AbbVie, Eli Lilly, Janssen, Novartis, and Celgene. |
|
| Reprints are not available from the authors. |
Vol 82 - N° 1
P. 213-221 - janvier 2020 Retour au numéro
Article précédent
- The human papillomavirus vaccine as a treatment for human papillomavirus–related dysplastic and neoplastic conditions: A literature review
- Christine T. Pham, Margit Juhasz, Calvin T. Sung, Natasha Atanaskova Mesinkovska
- The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis
- Taylor E. Woo, Christopher D. Sibley
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?